Case series:apatinib mesylate

4 trials

Sponsors

Cancer Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, The First Hospital of Jilin University, Fujian Provincial Cancer Hospital

Conditions

HER2 negative breast cancerlung cancermalignant brain Metastases with peritumoral edema after radiotherapytreatment of recurrent / metastatic head and neck squamous cell carcinoma

Phase 2

A Prospective, Multi-Center, Single-Arm study of efficacy and safety of apatinib mesylate in the treatment of recurrent and / or metastatic head and neck squamous cell carcinoma with one-line / multi-line chemotherapy failure

RecruitingChiCTR1800015278

Cancer Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technologytreatment of recurrent / metastatic head and neck squamous cell carcinoma

Start: 2017-07-19Updated: 2018-03-26

Phase 4

Real-World Study of Apatinib in the Treatment of Advanced Lung Cancer

Active, not recruitingChiCTR1800018113

Fujian Provincial Cancer Hospitallung cancer

Start: 2018-10-15Updated: 2018-09-03

Unknown Phase

Prospective, open, multicenter, single arm clinical study of atapatinib combined with docetaxel in the treatment of HER2 negative breast cancer with a first-line to three line chemotherapy failure

RecruitingChiCTR1800016103

Cancer Center,Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyHER2 negative breast cancer

Start: 2018-05-02Updated: 2018-05-14

Single arm single Center Clinical study of Apatinib Mesylate in the treatment of malignant brain Metastases with peritumoral edema after radiotherapy

RecruitingChiCTR1800018073

The First Hospital of Jilin Universitymalignant brain Metastases with peritumoral edema after radiotherapy

Start: 2018-09-01Updated: 2018-09-03

Related Papers

Efficacy and safety of apatinib as second-line or beyond therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Journal of Clinical Oncology2019-05-20